0001127602-24-014456.txt : 20240507 0001127602-24-014456.hdr.sgml : 20240507 20240507164844 ACCESSION NUMBER: 0001127602-24-014456 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240503 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NABEL ELIZABETH G CENTRAL INDEX KEY: 0001619929 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 24922837 MAIL ADDRESS: STREET 1: BRIGHAM AND WOMEN'S HOSPITAL STREET 2: 75 FRANCIS ST CITY: BOSTON STATE: MA ZIP: 02115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-05-03 0001682852 Moderna, Inc. MRNA 0001619929 NABEL ELIZABETH G C/O MODERNA, INC. 325 BINNEY STREET CAMBRIDGE MA 02142 1 0 Common Stock 2024-05-03 4 M 0 732 A 2105 D Restricted Stock Units 2024-05-03 4 M 0 732 0 D Common Stock 732 0 D Stock Option (Right to Buy) 122.13 2024-05-06 4 A 0 5668 0 A 2034-05-06 Common Stock 5668 5668 D Restricted Stock Units 2024-05-06 4 A 0 979 0 A Common Stock 979 979 D Restricted stock units convert into common stock on a one-for-one basis. The shares subject to this restricted stock unit award vested in full on May 3, 2024. This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. /s/ Brian Sandstrom, as Attorney-in-Fact 2024-05-07